1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Abbott Laboratories

Abbott Laboratories

ABT.SW
Abbott LaboratoriesCH flagSwiss Exchange
72.50
CHF
-2.00
- -
126.28BMarket Cap
Abbott Laboratories
ABT.SW
(Swiss Exchange)

Recent

price

72.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
22.73
13.63
12.08
12.7
13.43
13.86
14.16
15.71
17.42
18.1
19.54
24.42
25.12
23.13
24.22
25.53
25.95
Revenue per Share
2.99
3.01
3.78
1.66
1.51
3
0.95
0.27
1.35
2.09
2.54
4.01
3.99
3.3
7.74
3.76
3.61
Basic EPS, GAAP
4.99
4.76
4.77
1.41
1.72
1.26
1.41
2.54
2.79
2.55
3.23
4.9
4.49
2.92
3.67
4.26
4.24
Free Cash Flow per Basic Share
1.73
1.87
2.02
0.57
0.89
0.98
1.04
1.06
1.12
1.29
1.45
1.82
1.9
2.05
2.22
2.37
2.41
Dividend per Share
18.07
19.57
22.77
21.98
23.38
26.14
26.2
27.06
27.38
28.2
29.23
31.74
34.51
36
41.82
43.37
43.29
Book Value per Share
-3.44
-0.74
1.55
6.3
3.56
4.16
5.77
-8.26
-6.54
-5.06
-3.12
0.03
2.1
3.65
10.48
13.37
-0.23
Tangible Book Value per Share
1,547
1,570
1,577
1,548
1,508
1,473
1,473
1,744
1,756
1,763
1,771
1,764
1,738
1,734
1,732
1,737
1,739
Basic Weighted Avg Shares
35,167
21,407
19,050
19,657
20,247
20,405
20,853
27,390
30,578
31,904
34,608
43,075
43,653
40,109
41,950
44,328
45,134
Sales/Revenue/Turnover
18.2
7.61
7.14
10.85
12.84
14.05
14.51
5.71
11.94
14.21
15.48
19.56
19.16
16.15
16.27
18.17
17.07
Operating Margin (%)
2,624
3,044
2,782
1,719
1,548
1,472
1,353
3,021
3,278
3,014
3,327
3,538
3,267
3,243
3,218
3,116
3,163
Depreciation Expense
4,626
4,728
5,963
2,576
2,284
4,423
1,400
477
2,368
3,687
4,495
7,071
6,933
5,723
13,402
6,524
6,276
Net Income, GAAP
19.02
8.9
- -
2.6
31.65
18.13
24.77
84.18
18.76
9.57
10
13.88
16.53
14.12
- -
22.94
22.87
Effective Tax Rate (%)
13.15
22.09
31.3
13.1
11.28
21.68
6.71
1.74
7.74
11.56
12.99
16.42
15.88
14.27
31.95
14.72
13.91
Profit Margin (%)
5,055
8,289
18,043
9,740
3,089
4,969
20,116
11,235
5,620
4,804
8,534
11,134
9,735
8,829
9,499
9,500
7,131
Working Capital
12,524
12,040
18,085
3,388
3,393
5,871
20,681
27,210
19,359
17,416
19,429
18,252
15,465
14,548
13,521
10,827
29,638
LT Debt
22,765
24,526
26,813
25,267
21,639
21,326
20,717
31,098
30,722
31,301
33,003
36,024
36,905
38,827
47,901
52,771
52,701
Total Equity
12.58
3.59
- -
5.24
5.81
7.84
6.23
0.49
5.43
8.17
9.4
13.51
12.77
10.21
- -
9.56
7.97
Return on Invested Capital (%)
12.6
10.85
- -
5.59
5.69
10.04
3.18
0.91
4.25
6.28
7.1
10.25
9.66
8.03
- -
7.78
6.81
Return on Capital (%)
20.55
16.11
17.9
7.37
6.59
11.99
3.63
1.11
4.97
7.54
8.86
13.12
11.96
9.35
19.88
8.83
8.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,345
3,033
4,409
LT Borrowings
11,596
9,896
29,638
LT Finance Leases
- -
931
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,739
1,737
1,742
Market Capitalization
222,514
217,309
179,560

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
24,839
25,996
25,508
Cash, Cash Equivalents & STI
7,733
8,939
7,295
Accounts Receivable, Net
8,138
7,929
8,210
Inventories
6,708
6,488
6,989
Total Current Liabilities
14,582
16,496
18,377
Payables & Accruals
13,237
13,463
13,968
ST Debt
1,345
3,033
4,409
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.37%
10.07%
10.17%
Free Cash Flow
20.29%
9.63%
16.44%
Net Income, GAAP
46.05%
24.15%
-51.32%
Sales/Revenue/Turnover
8.6%
5.59%
5.67%
Total Cash Common Dividend
11.24%
10.21%
7.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,964
10,377
10,635
10,974
41,950
2025
10,358
11,142
11,369
11,459
44,328
2026
11,164
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
0.75
0.95
5.33
7.74
2025
0.76
1.02
0.95
1.02
3.76
2026
0.62
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
0.55
0.55
0.55
2.22
2025
0.59
0.59
0.59
0.59
2.37
2026
0.63
- -
- -
- -
- -
Similar Companies
Endymed Ltd (ENDY.TA)
Coala-Life Group AB (publ) (COALA.ST)
Stimcell Energetics, Inc. (STME)
Beijing Succeeder Technology Inc. (688338.SS)
Arcoma AB (ARCOMA.ST)
EOFLOW Co.,Ltd. (294090.KQ)
Business
Abbott Laboratories Abbott Laboratories is a multinational medical devices and health care company that develops, manufactures and markets a broad range of products including diagnostic systems such as ARCHITECT clinical chemistry and immunoassay analyzers, Alinity platforms, i-STAT point-of-care analyzers, ID NOW molecular diagnostics and BinaxNOW rapid tests; nutritional products encompassing pediatric formulas like Similac, Isomil, Pedialyte and PediaSure alongside adult nutritionals including Ensure, Glucerna, ZonePerfect and Juven; medical devices comprising cardiovascular solutions such as MitraClip structural heart devices, XIENCE stents, Epic and Trifecta tissue valves, EnSite mapping systems and Aveir leadless pacemakers, diabetes care technologies like FreeStyle Libre continuous glucose monitors, and neuromodulation systems including Proclaim spinal cord stimulators and Infinity deep brain stimulators; as well as branded generic pharmaceuticals sold primarily in emerging markets. The company, founded in 1888 and headquartered in Abbott Park, Illinois, operates in over 160 countries with a workforce exceeding 114,000 employees, serving hospitals, laboratories, physicians' offices, retailers, government agencies and consumers worldwide through its core segments of diagnostics, medical devices, nutrition and established pharmaceuticals. In November 2025, Abbott Laboratories agreed to acquire Exact Sciences Corp. for approximately $21 billion in cash to expand its diagnostics portfolio with cancer screening technologies including Cologuard for colorectal cancer and multi-cancer early detection tests, a transaction expected to close in the second quarter of 2026 subject to approvals and poised to elevate annual diagnostics sales beyond $12 billion.